Powder: -20°C for 3 years | In solvent: -80°C for 1 year
c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1]
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1] |
In vitro | c-Met-IN-17 (compound 29) demonstrated an IC50 value of 0.068 μM for the inhibition of D1228V c-MET enzymatic activity, as measured by the ADP-Glo assay [1]. |
In vivo | c-Met-IN-17, administered intravenously at a dose of 0.5 mg/kg to Wistar rats, demonstrated excellent bioavailability over a 24-hour period [1]. Pharmacokinetic analysis in Wistar rats [1] revealed the following parameters: clearance (Cl) at 60 mL/min/kg, steady-state volume of distribution (Vss_obs) at 4.6 L/kg, and a bioavailability of 100%. |
Molecular Weight | 374.37 |
Formula | C21H15FN4O2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
c-Met-IN-17 Tyrosine Kinase/Adaptors c-Met/HGFR inhibitor inhibit